LT - (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
EN - (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
Legal status
Patent not validated
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
A61K 31/4375 |
(2006.01) |
|
|
A61K 31/513 |
(2006.01) |
|
|
A61P 35/02 |
(2006.01) |
|
|
A61K 45/06 |
(2006.01) |
|
|
A61K 31/53 |
(2006.01) |
European patent
| (11) |
Number of the document |
2649997 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
13166632.3 |
|
Date of filing the European patent application |
2008-12-10 |
| (97) |
Date of publication of the European application |
2013-10-16 |
| (45) |
Date of publication and mention of the grant of the patent |
2019-01-23
|
| (46) |
Date of publication of the claims translation |
|
Priority applications
| (30) |
Number |
Date |
Country code |
|
7229 P |
2007-12-10
|
US |
Inventors
| (72) |
Michelson, Glenn, US
|
Grantee
| (73) |
Sunesis Pharmaceuticals, Inc.,
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080,
US
|
Title
| (54) |
(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| |
(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
